CoChat

Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy

Open access
Newman, Nancy J, Yu-Wai-Man, Patrick, Subramanian, Prem S, Moster, Mark L, Wang, An-Guor, Donahue, Sean P, Leroy, Bart P, Carelli, Valerio, Biousse, Valerie, Vignal-Clermont, Catherine, Sergott, Robert C, Sadun, Alfredo A, Rebolleda Fernández, Gema, Chwalisz, Bart K, Banik, Rudrani, Bazin, Fabienne, Roux, Michel, Cox, Eric D, Taiel, Magali, Sahel, José-Alain, the LHON REFLECT Study Group, Giulia, Amore, Shweta, Anand, Rudrani, Banik, Piero, Barboni, Valérie, Biousse, Hayley, Boston, Asma, Burale, Michele, Carbonelli, Valerio, Carelli, Celia, Chen, Hui-Chen, Cheng, Steve, Cho, Chwalisz, Bart K, Manuela, Contin, Pietro, D’Agati, DeBusk, Adam A, Julie, De Zaeytijd, Jannah, Dobbs, Donahue, Sean P, Lindreth, DuBois, Simona, Esposti, Alcides, Fernandes Filho, Elizabeth, Fortin, Sapna, Gangaputra, Deborah, Gibbs, François, Girmens Jean, Rabih, Hage, Haller, Julia A, Gad, Heilweil, George Baker, Hubbard III, Jeong-Min, Hwang, Laia, Jaumendreu Urquijo, Neringa, Jurkute, Rustum, Karanjia, Wahiba, Khemliche, La Chiara, Morgia, Leroy, Bart P, Maria, Massini, Marc, Mathias, Memon, Muhammad A, Susan, Mohamed, Moster, Mark L, Muñoz Negrete, Francisco J, Newman, Nancy J, Ghazala, O’Keefe, Shriji, Patel, Paula, Pecen, Peragallo, Jason H, Lise, Plaine, Mary, Preston, Gema, Rebolleda Fernández, Martina, Romagnoli, Sadun, Alfredo A, José-Alain, Sahel, Melissa, SantaMaria, Sergott, Robert C, Subramanian, Prem S, Chuanbin, Sun, Katy, Tai, Heather, Tollis, Irena, Tsui, Tucker, William R, Catherine, Vignal-Clermont, An-Guor, Wang, Saige, Wilkins, Patrick, Yu-Wai-Man · 2023 · Brain

The DOI matches its Crossref record; 46 of the 48 references it cites were found in a registry or an index; 41 of the 57 sources its claims cite were checked for support.

Abstract

Leber hereditary optic neuropathy (LHON) is an important example of mitochondrial blindness with the m.11778G>A mutation in the MT-ND4 gene being the most common disease-causing mtDNA variant worldwide. The REFLECT phase 3 pivotal study is a randomized, double-masked, placebo-controlled trial investigating the efficacy and safety of bilateral intravitreal injection of lenadogene nolparvovec in patients with a confirmed m.11778G>A mutation, using a recombinant adeno-associated virus vector 2, serotype 2 (rAAV2/2-ND4). The first-affected eye received gene therapy; the fellow (affected/not-yet-affected) eye was randomly injected with gene therapy or placebo. The primary end point was the difference in change from baseline of best-corrected visual acuity (BCVA) in second-affected/not-yet-affected eyes treated with lenadogene nolparvovec versus placebo at 1.5 years post-treatment, expressed in logarithm of the minimal angle of resolution (LogMAR). Forty-eight patients were treated bilaterally and 50 unilaterally. At 1.5 years, the change from baseline in BCVA was not statistically different between second-affected/not-yet-affected eyes receiving lenadogene nolparvovec and placebo (primary end point). A statistically significant improvement in BCVA was reported from baseline to 1.5 years in lenadogene nolparvovec-treated eyes: −0.23 LogMAR for the first-affected eyes of bilaterally treated patients (P < 0.01); and −0.15 LogMAR for second-affected/not-yet-affected eyes of bilaterally treated patients and the first-affected eyes of unilaterally treated patients (P < 0.05). The mean improvement in BCVA from nadir to 1.5 years was −0.38 (0.052) LogMAR and −0.33 (0.052) LogMAR in first-affected and second-affected/not-yet-affected eyes treated with lenadogene nolparvovec, respectively (bilateral treatment group). A mean improvement of −0.33 (0.051) LogMAR and −0.26 (0.051) LogMAR was observed in first-affected lenadogene nolparvovec-treated eyes and second-affected/not-yet-affected placebo-treated eyes, respectively (unilateral treatment group). The proportion of patients with one or both eyes on-chart at 1.5 years was 85.4% and 72.0% for bilaterally and unilaterally treated patients, respectively. The gene therapy was well tolerated, with no systemic issues. Intraocular inflammation, which was mostly mild and well controlled with topical corticosteroids, occurred in 70.7% of lenadogene nolparvovec-treated eyes versus 10.2% of placebo-treated eyes. Among eyes treated with lenadogene nolparvovec, there was no difference in the incidence of intraocular inflammation between bilaterally and unilaterally treated patients. Overall, the REFLECT trial demonstrated an improvement of BCVA in LHON eyes carrying the m.11778G>A mtDNA mutation treated with lenadogene nolparvovec or placebo to a degree not reported in natural history studies and supports an improved benefit/risk profile for bilateral injections of lenadogene nolparvovec relative to unilateral injections.

Overview

CoChat Summary

TL;DR

REFLECT, a phase 3 randomized, double-masked, placebo-controlled trial, tested bilateral intravitreal lenadogene nolparvovec in patients with m.11778G>A MT-ND4 Leber hereditary optic neuropathy. The primary endpoint comparing second-affected/not-yet-affected eyes treated with gene therapy versus placebo at 1.5 years was not met, although treated eyes improved and bilateral treatment showed better visual outcomes than unilateral treatment.

Key findings

  • The primary endpoint was not met: the least squares mean difference in BCVA change from baseline to 1.5 years between second-affected/not-yet-affected lenadogene nolparvovec- and placebo-treated eyes was −0.05 LogMAR (P = 0.6080, ANCOVA), below the prespecified clinically significant difference of −0.3 LogMAR.
  • In lenadogene nolparvovec-treated eyes, BCVA improved from baseline to 1.5 years: by linear mixed model, first-affected eyes of bilaterally treated patients improved −0.23 (0.070) LogMAR (+12 ETDRS letters, P < 0.01), while second-affected/not-yet-affected eyes of bilaterally treated patients and first-affected eyes of unilaterally treated patients each improved −0.15 LogMAR (+8 ETDRS letters, P < 0.05).
  • From nadir to 1.5 years, all eye groups improved significantly (P < 0.0001); by linear mixed model, first-affected and second-affected/not-yet-affected eyes treated with lenadogene nolparvovec in the bilateral group improved −0.38 (0.052) and −0.33 (0.052) LogMAR, respectively, while first-affected lenadogene-treated and second-affected placebo-treated eyes in the unilateral group improved −0.33 (0.051) and −0.26 (0.051) LogMAR.
  • Intraocular inflammation occurred in 70.7% of lenadogene nolparvovec-treated eyes versus 10.2% of placebo-treated eyes, was mostly mild and controlled with topical corticosteroids, and did not differ in incidence between bilaterally and unilaterally treated patients among gene-therapy eyes; no systemic life-threatening AEs, deaths, or serious ocular AEs were reported.

Methods

  • Phase 3, pivotal, randomized, double-masked, placebo-controlled study at 13 centres in seven countries; 98 patients with m.11778G>A MT-ND4 LHON and vision loss ≤1 year were randomized 1:1 to bilateral treatment (48 patients) or unilateral treatment (50 patients).
  • In both arms, the first-affected eye received lenadogene nolparvovec; the second-affected/not-yet-affected eye was randomized to lenadogene nolparvovec or placebo (balanced salt solution). Dose was 9 × 10^10 vector genomes in 90 µl per eye.
  • Primary endpoint was the difference in change from baseline to 1.5 years in LogMAR BCVA between second-affected/not-yet-affected lenadogene- and placebo-treated eyes; analyses used ANCOVA and a prespecified linear mixed model sensitivity analysis in SAS v9.4.

Limitations

  • The paper states that the contralateral effect in unilaterally treated patients means contralateral placebo/sham eyes are not appropriate controls; the lack of a patient placebo-controlled arm requires indirect comparison with published natural history data, which were not prospective and had inconsistent data acquisition.
  • The paper also states that the baseline BCVA primary endpoint is problematic because disease onset ranged within 12 months and baseline BCVA was inhomogeneous; nadir BCVA may be a more clinically relevant reference, though eyes can only improve from nadir.
  • The text makes evident that the primary endpoint was not met and that improvements in treated eyes are partly interpreted against natural history rather than a randomized untreated control; possible eccentric fixation contribution is also noted by the authors.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/brain/awac421

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 REFLECT study design. Asterisk indicates the allocated study treatment was administered on the same day (Day 0) or on two consecutive days (Day −1 and Day 0) at the investigator’s discretion. In all cases, the initial treatment administration had to be performed the day following the Inclusion visit; thus, the Inclusion visit was performed on Day −1 if eyes were treated on the same day, or on Day −2 if eyes were treated on 2 consecutive days. #Participation in the long-term follow-up phase of the study up to Year 5 was/will be sought at the Year 2 visit with a separate informed consent. For patients who did not consent to participate in the long-term follow-up period, the end-of-study visit was the Year 2 visit. D = day; W = week; Y = year.
Figure 1 REFLECT study design. Asterisk indicates the allocated study treatment was administered on the same day (Day 0) or on two consecutive days (Day −1 and Day 0) at the investigator’s discretion. In all cases, the initial treatment administration had to be performed the day following the Inclusion visit; thus, the Inclusion visit was performed on Day −1 if eyes were treated on the same day, or on Day −2 if eyes were treated on 2 consecutive days. #Participation in the long-term follow-up phase of the study up to Year 5 was/will be sought at the Year 2 visit with a separate informed consent. For patients who did not consent to participate in the long-term follow-up period, the end-of-study visit was the Year 2 visit. D = day; W = week; Y = year.CC BY-NC · PubMed Central
Figure 2 Participants flow at the 1.5 year interim analysis. TARM1: First-affected eye and second-affected/not-yet-affected eye administered lenadogene nolparvovec. TARM2: First-affected eye administered lenadogene nolparvovec, second-affected/not-yet-affected eye administered placebo. *Taking in account reassigned visit at Year 1.5 as per the rules described in the ‘Statistical analyses’ section.
Figure 2 Participants flow at the 1.5 year interim analysis. TARM1: First-affected eye and second-affected/not-yet-affected eye administered lenadogene nolparvovec. TARM2: First-affected eye administered lenadogene nolparvovec, second-affected/not-yet-affected eye administered placebo. *Taking in account reassigned visit at Year 1.5 as per the rules described in the ‘Statistical analyses’ section.CC BY-NC · PubMed Central
Figure 3 Time course of LS mean change in LogMAR BCVA from baseline to 1.5 years for first-affected and second-affected/not-yet-affected eyes—estimated by ANCOVA model (ITT population). An ANCOVA model (considering both eyes of each patient) was used to model the change from baseline to time point of interest for LogMAR BCVA, using baseline LogMAR as covariate and treatment as fixed effect. Data are shown as LS mean.
Figure 3 Time course of LS mean change in LogMAR BCVA from baseline to 1.5 years for first-affected and second-affected/not-yet-affected eyes—estimated by ANCOVA model (ITT population). An ANCOVA model (considering both eyes of each patient) was used to model the change from baseline to time point of interest for LogMAR BCVA, using baseline LogMAR as covariate and treatment as fixed effect. Data are shown as LS mean.CC BY-NC · PubMed Central

Verification

Claims the paper makes

17 Valid · 3 Not valid · 10 Not checked · 139 Own results and interpretations

99 more claims · 4 with their cited sources checked

Create a free account to see all 169 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 58
  • Probably not a substantial claim. 19

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Cited by

See all 87

Metadata

Authors
Newman, N. J., Yu-Wai-Man, P., Subramanian, P. S., Moster, M. L., Wang, A.-G., Donahue, S. P., Leroy, B. P., Carelli, V., Biousse, V., Vignal-Clermont, C., Sergott, R. C., Sadun, A. A., Rebolleda Fernández, G., Chwalisz, B. K., Banik, R., Bazin, F., Roux, M., Cox, E. D., Taiel, M., Sahel, J.-A., the LHON REFLECT Study Group, Giulia, A., Shweta, A., Rudrani, B., Piero, B., Valérie, B., Hayley, B., Asma, B., Michele, C., Valerio, C., Celia, C., Hui-Chen, C., Steve, C., Chwalisz, B. K., Manuela, C., Pietro, D., DeBusk, A. A., Julie, D. Z., Jannah, D., Donahue, S. P., Lindreth, D., Simona, E., Alcides, F. F., Elizabeth, F., Sapna, G., Deborah, G., François, G. J., Rabih, H., Haller, J. A., Gad, H., George Baker, H. I., Jeong-Min, H., Laia, J. U., Neringa, J., Rustum, K., Wahiba, K., La Chiara, M., Leroy, B. P., Maria, M., Marc, M., Memon, M. A., Susan, M., Moster, M. L., Muñoz Negrete, F. J., Newman, N. J., Ghazala, O., Shriji, P., Paula, P., Peragallo, J. H., Lise, P., Mary, P., Gema, R. F., Martina, R., Sadun, A. A., José-Alain, S., Melissa, S., Sergott, R. C., Subramanian, P. S., Chuanbin, S., Katy, T., Heather, T., Irena, T., Tucker, W. R., Catherine, V.-C., An-Guor, W., Saige, W., & Patrick, Y.-W.-M.
Affiliations
  • Cambridge Centre for Brain Repair and MRC Mitochondrial Biology Unit, Department of Clinical Neurosciences, University of Cambridge , Cambridge , UK
  • Department of Ophthalmology, Taipei Veterans General Hospital, National Yang Ming Chiao Tung University , Taipei , Taiwan
  • IRCCS Istituto delle Scienze Neurologiche di Bologna, Programma di Neurogenetica , Bologna , Italy
  • Departments of Ophthalmology, Neurology and Neurological Surgery, Emory University School of Medicine , Atlanta, GA , USA
  • Department of Neuro Ophthalmology and Emergencies, Rothschild Foundation Hospital , Paris , France
  • Department of Ophthalmology, Alcala University , Madrid , Spain
  • Department of Ophthalmology, Icahn School of Medicine at Mount Sinai , New York, NY , USA
  • eXYSTAT, Data Management and Statistics , Paris , France
  • GenSight Biologics (France) (FR)
  • Sorbonne Université, INSERM, CNRS, Institut de la Vision , Paris , France
  • Emory University (US)
  • Centre hospitalier national d'ophtalmologie des Quinze-Vingts (FR)
  • University of Cambridge (GB)
Venue
Brain
Published
2022-11-09
Volume
146
Issue
4
Pages
1328-1341
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W4308638146
Cited by
87
References
48
Citations by year
2026: 19 · 2025: 25 · 2024: 29 · 2023: 11 · 2022: 3
FWCI
10.26
Type
journal article
Language
en
Open access
Locations
  • Brain (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by-nc)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
Funders
GenSight Biologics
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
Keywords
Leber's hereditary optic neuropathy, m.11778G>A mutation, MT-ND4, intravitreal injection, best-corrected visual acuity, REFLECT trial, recombinant adeno-associated virus vectors, gene therapy
MeSH terms
Dependovirus, DNA, Mitochondrial, Humans, Inflammation, Mutation, NADH Dehydrogenase, Genetic Therapy, Optic Atrophy, Hereditary, Leber

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.